



## Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.  
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243  
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

20<sup>th</sup> March, 2026

Corporate Relationship Department  
M/s. BSE Limited  
Mumbai 400001

The Manager - Listing  
M/s. National Stock Exchange of India Ltd  
Bandra (E), Mumbai 400051

**Scrip Code: 524816**

**Scrip Code: NATCOPHARM**

Dear Sir/Madam,

**Sub:-** Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290.

This is for your information and records.

Thanking you,

Yours faithfully,  
For NATCO Pharma Limited

Ch. Venkat Ramesh  
Company Secretary &  
Compliance Officer

Encl: As above

**NATCO Pharma Ltd**

NATCO House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**NATCO Pharma Launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290**

Hyderabad, India, March 20<sup>th</sup>, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") announces launch of Semaglutide Injection (multi dose vials) in the India market tomorrow on Day 1 of patent expiry.

NATCO received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture and market generic Semaglutide in India in February'26 for multi dose vials and pen device based on the clinical comparison study. Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.

NATCO plans to launch Semaglutide injection in the form of multi dose vials of strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml under the brand names SEMANAT™ and SEMAFULL™. Multi dose vials will be launched at MRP of INR 1,290 per month for 2 mg/1.5ml & 4mg/3ml and MRP of INR 1,750 for 8mg/3ml.

Pen device will be priced at MRP of INR 4,000, INR 4,200 and INR 4,500 per month for the strengths 2mg/1.5ml, 4mg/3ml and 8mg/3ml respectively. Pen device is expected to be launched in April'26.

NATCO is the first company to offer generic Semaglutide in multi dose vials with customised syringes. NATCO is also offering the product to third parties for co-marketing.

NATCO is the first company to offer Semaglutide in the vial dosage form. It is the most affordable GLP-1 currently in the Indian market as it is approximately 70% cheaper in cost than the pen device and 90% cheaper than the price of the innovator's brand. This will increase patient accessibility to the GLP-1 therapy and would help in long term compliance for the patients.

**About NATCO Pharma Limited**

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's different manufacturing facilities are approved by several leading regulatory authorities like U.S. FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at [www.natcopharma.com](http://www.natcopharma.com).



## NATCO Pharma Ltd

NATCO House  
Road No.2, Banjara Hills  
Hyderabad-500 034, India

**For further information or queries please contact:**

Rajeev Menon – Manager, Investor Relations  
Email: [r.menon@natcopharma.co.in](mailto:r.menon@natcopharma.co.in)

Rajesh Chebiyam – EVP, Crop Health Sciences  
Email: [investors@natcopharma.co.in](mailto:investors@natcopharma.co.in)

Tel: 040-23547532 / Ext – 323

**Follow us on:**

X (formerly Twitter): [https://twitter.com/pharma\\_natco](https://twitter.com/pharma_natco)

LinkedIn: <https://www.linkedin.com/company/natcopharma>